SCHEMBL4864154

SCHEMBL4864154

O=c1c([N+](=O)[O-])c(-c2cnn(-c3ccccc3)c2)n(CCc2ccccc2)c(=O)n1C1CCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.38
MTOR P42345 1/20 0.37
ADORA2A P29274 1/20 0.35
ADORA2B P29275 1/20 0.35
ADORA1 P30542 1/20 0.35
CACNA1G O43497 2/20 0.34
CACNA1H O95180 2/20 0.34
ALDH1A1 P00352 5/20 0.33
NPSR1 Q6W5P4 3/20 0.33
CRHBP P24387 2/20 0.33
CRHR2 Q13324 2/20 0.33
POLB P06746 1/20 0.33
HPGD P15428 3/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
DRD2 P14416 2/20 0.32
DRD4 P21917 2/20 0.32
DRD3 P35462 2/20 0.32
TSHR P16473 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PDE4B Q07343 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4867656 0.90 CACNA1G (0.36) ADORA2AADORA2BADORA1CACNA1GCACNA1H
SCHEMBL4858967 0.86 HSP90AA1 (0.44) HSP90AA1MTORADORA2AADORA2BADORA1
SCHEMBL4859903 0.86 HSP90AA1 (0.44) HSP90AA1ADORA2AADORA2BADORA1ALDH1A1
SCHEMBL4792629 0.83 SMN1; SMN2 (0.35) HSP90AA1MTORCACNA1GCACNA1HALDH1A1
SCHEMBL4867818 0.83 ADORA2B (0.39) ADORA2AADORA2BADORA1ALDH1A1NPSR1
SCHEMBL4866193 0.82 PDE4A (0.39) HSP90AA1MTORADORA2AADORA2BADORA1
SCHEMBL4891723 0.81 C5AR1 (0.42) ADORA2AADORA2BADORA1
SCHEMBL4864147 0.80 HSP90AA1 (0.41) HSP90AA1MTORADORA2AADORA2BADORA1
SCHEMBL4868140 0.79 ADORA1 (0.42) HSP90AA1ADORA2AADORA2BADORA1ALDH1A1
SCHEMBL4769064 0.77 CACNA1G (0.41) ADORA2BCACNA1GCACNA1HALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7449473-B2 Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2008-11-11 US disclosed
EP-1678181-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2006-07-12 EP disclosed
US-20050119287-A1 A2B adenosine receptor antagonists GILEAD PALO ALTO, INC. 2005-06-02 US disclosed
WO-2005042534-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119287-A1 A2B adenosine receptor antagonists ADORA2B, ADORA2A, ADORA3 HSP90AA1 1863/4885MTOR 2711/4885ADORA2A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.